Abraxane monotherapy is indicated for the treatment of metastatic breast cancer The recommended dose of Abraxane in combination with gemcitabine is Attachment 1: Product information for AusPAR Abraxane paclitaxel (nab) Abraxis PM Date of Finalisation 17 June This Product. Learn more about ABRAXANE®, including dosing, efficacy, and safety information. This site is intended for US healthcare professionals only.

Author: Misar Gardajind
Country: Mozambique
Language: English (Spanish)
Genre: Education
Published (Last): 19 June 2014
Pages: 83
PDF File Size: 14.92 Mb
ePub File Size: 20.96 Mb
ISBN: 665-2-96884-658-9
Downloads: 23129
Price: Free* [*Free Regsitration Required]
Uploader: Tygor

That feature is of particular clinical importance for women with early-stage breast cancer who relapse within 12 months of exposure to a solvent-based taxane.

Nab-paclitaxel was well tolerated, with the primary toxicity being mild sensory neuropathy. Demographic and treatment characteristics of patients with metastatic breast cancer receiving nab-paclitaxel.

ABRAXANE – Prescribing Information

Author information Copyright and License information Disclaimer. This article has been cited by other articles in PMC.

It is this drug entrapment phenomenon that partly explains why giving higher doses of solvent-based paclitaxel does not result in improved clinical efficacy Dose reductions, mainly because of toxicity, were more abrxaane with q3w administration Agraxane Between June and December43 patients with mbc received treatment with single-agent nab-paclitaxel at the Ottawa Hospital Cancer Centre, and 42 patients were evaluable for clinical response.


Grade 2 fatigue was reported in 4 patients 9.

Sensory neuropathy was the primary toxicity Find articles by M. Paclitaxel is entrapped by the formation of plasma Cremophor EL micelles, which can cause reduced drug clearance, nonlinear pharmacokinetics, and free drug fraction Traditional solvent-based taxanes have been shown to be beneficial in the treatment of mbc.

Open in a separate window. Nab-paclitaxel was administered weekly qw: Women who received nab-paclitaxel qw had a median overall survival of Women who experienced clinical benefit from nab-paclitaxel survived significantly longer than those who abrqxane not Table i summarizes patient demographics and treatment characteristics.

Cancer and Leukemia Group B trial Phase iii trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil—based paclitaxel in women with breast cancer. Nab-paclitaxel, taxane, mbcAbraxane. Although the median overall survival for all women treated agraxane nab-paclitaxel was Clinical benefit was achieved in 24 patients Regardless of the schedule of administration, women who experienced clinical benefit from nab-paclitaxel lived significantly longer than those who did not achieve clinical benefit [ Nab-paclitaxel represents abraaxane treatment option, with a favourable toxicity profile, for women with mbc.

Survival curves for patients who achieved and did not achieve clinical benefit from nab-paclitaxel. Clinical benefit was evaluable in 42 patients.


ABRAXANE | Full Prescribing Information

In our experience, most women with mbc treated with single-agent nab-paclitaxel some having received up to 6 prior lines of chemotherapy experienced some degree of clinical benefit with an acceptable level of toxicity. Data were collected retrospectively on a select group of patients who received nab-paclitaxel if they had private insurance coverage or met the eligibility criteria for the Ontario New Drug Funding Program, creating a potential for selection bias.

Albumin-bound paclitaxel ab-pac versus docetaxel for first-line treatment of metastatic breast cancer mbc: This study was supported with an unrestricted educational grant provided by Celgene Canada formerly Abraxis BioSciences. TABLE II Clinical outcomes data in patients with metastatic breast cancer receiving nab-paclitaxel on a weekly qw and everyweeks q3w schedule. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: J Clin Oncol ; In addition, there was a potential imbalance in prognostic factors among patients who received the qw schedule and those who received the q3w schedule of nab-paclitaxel.